We are excited to announce we entered into an agreement with K2 HealthVentures to provide a credit facility of up to $150 million, extending cash runway into 2028. We also announced progress and updated timelines for all ongoing trials.
Read more: https://t.co/OgfF2X6Aiw
Tune in tomorrow at 3:00 pm ET to hear our fireside chat at the H.C. Wainwright 4th Annual BioConnect Nasdaq Investor Conference. Listen to the webcast here: https://t.co/MtLWizyjYZ
#celltherapy#autoimmunity
Today we reported first quarter 2026 financial results and provided a business update. Full press release: https://t.co/EnpeynN83R
#celltherapy#autoimmunity
We attended the @AANmember 2026 Annual Meeting this week! We had a lovely time connecting with researchers and doctors from around the world on new and exciting potential therapies for #MG. Learn more about our Ph3 AURORA trial: https://t.co/dGdiUbnM73
#CellTherapy#Autoimmune
Our team attended the @MyastheniaOrg National Patient Conference this week! It was great to meet and connect with patients, families, advocates and #MG experts throughout the event. To learn more about our Phase 3 AURORA trial: https://t.co/NT0uoYZf3n
Tune in tomorrow at 9:30 am ET to hear our fireside chat at the Needham Virtual Healthcare Conference. Listen to the webcast here: https://t.co/mThEaaPfc3
#celltherapy#autoimmunity
Tune in tomorrow at 9:30 am ET to hear our fireside chat at the Needham Virtual Healthcare Conference. Listen to the webcast here: https://t.co/mThEaaPfc3
#celltherapy#autoimmunity
Last month we participated in Cantor's #RareDiseaseDay webinar series discussing #Myositis, a rare set of pathogenic autoantibody-driven diseases characterized by inflammation and muscle weakness that impacts ~80,000 people in the U.S. Learn more here: https://t.co/kKTfTI5WRi
Our team is on the ground at the International Myositis Society 6th Global Conference on Myositis kicking off today. Come see our posters and hear more about our work in #Myositis.
View our posters: https://t.co/DZEkSGUKrl
Learn more: https://t.co/kKTfTI5WRi
#RareDisease
We are at the @MDAorg congress this week. Come see our poster to hear more about our work in #myastheniagravis which was recently published in Nature Medicine! This will be our first time presenting this at a medical meeting. See our publications here: https://t.co/9WaYLlTrhb
Today we reported full year 2025 financial results and provided a business update. Full press release: https://t.co/ycucVuQ7qE
#celltherapy#autoimmunity
Tune in tomorrow at 10:00 am ET to hear our fireside chat at the Leerink Global Healthcare Conference in Miami, FL. Listen to the webcast here: https://t.co/Y1PJD07Je5
Tune in tomorrow at 11:50 am ET to hear our presentation at the TD Cowen 46th Annual Health Care Conference in Boston, MA. Listen to the webcast here: https://t.co/thEm1gGoQh
Our commitment to patients is at the heart of everything we do. We recently spoke with Cheryl about her experience navigating and managing an MG diagnosis. To view Cheryl’s full interview, please visit: https://t.co/lg3MIqU3Fl
#RareDiseaseDay#LightUpForRare#ShareYourColors
Looking forward to attending three upcoming investor conferences, where we’re discussing exciting company milestones ahead as we work to expand the reach of #celltherapy to #autoimmunedisease. Information here: https://t.co/AmAxMBDiOw
Thank you @DsLevine, for hosting us on #RareCAST, where we discussed our potential #celltherapy, data from our phase 2 study in myasthenia gravis, and the opportunity to expand the approach into #myositis and other rare autoimmune indications. To listen: https://t.co/jX4sUMwNVd
Myasthenia gravis (MG) is a chronic #autoimmune disorder that causes disabling muscle weakness and fatigue. Learn more about this #RareDisease directly from people living with MG and how this has affected their daily lives. Full interview: https://t.co/nd7GvIg7pE